Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meiqing Wu

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Transplantation|July 12, 2013
Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantationLi Xuan, Xinmiao Jiang, Jing Sun, et al.
Plos One|October 15, 2013
Herpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantationMeiqing Wu, Fen Huang, Xinmiao Jiang, et al.
SAGE Open Medicine|August 4, 2025
Prediction model for cytomegalovirus infection following hematopoietic stem cell transplantation in patients with β-thalassemia majorLin Pan, Zhenbin Wei, Yanni Xie, et al.
Cell Transplantation|January 9, 2013
Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective studyXiaodan Liu, Meiqing Wu, Yanwen Peng, et al.
Therapeutic Advances in Hematology|February 16, 2026
Comparing two different doses of anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent thalassemia: an open-label, randomized clinical trialQiulin Huang, Rongrong Liu, Baoshi Zheng, et al.
Oncoimmunology|July 29, 2016
Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantationXinmiao Jiang, Lanping Xu, Yu Zhang, et al.
American Journal of Hematology|January 2, 2023
Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trialHui Liu, Fen Huang, Yu Zhang, et al.
American Journal of Hematology|December 19, 2025
Basiliximab in the Prophylaxis of aGVHD for Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: A Prospective, Multicenter, Open-Label, Randomized Controlled StudyZhenbin Wei, Rongrong Liu, Lingling Shi, et al.
The Lancet. Haematology|February 7, 2025
Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trialSijian Yu, Fen Huang, Na Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2023
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III TrialYiwen Ling, Li Xuan, Na Xu, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Transplantation|July 12, 2013
Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantationLi Xuan, Xinmiao Jiang, Jing Sun, et al.
Plos One|October 15, 2013
Herpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantationMeiqing Wu, Fen Huang, Xinmiao Jiang, et al.
SAGE Open Medicine|August 4, 2025
Prediction model for cytomegalovirus infection following hematopoietic stem cell transplantation in patients with β-thalassemia majorLin Pan, Zhenbin Wei, Yanni Xie, et al.
Cell Transplantation|January 9, 2013
Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective studyXiaodan Liu, Meiqing Wu, Yanwen Peng, et al.
Therapeutic Advances in Hematology|February 16, 2026
Comparing two different doses of anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent thalassemia: an open-label, randomized clinical trialQiulin Huang, Rongrong Liu, Baoshi Zheng, et al.
Oncoimmunology|July 29, 2016
Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantationXinmiao Jiang, Lanping Xu, Yu Zhang, et al.
American Journal of Hematology|January 2, 2023
Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trialHui Liu, Fen Huang, Yu Zhang, et al.
American Journal of Hematology|December 19, 2025
Basiliximab in the Prophylaxis of aGVHD for Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: A Prospective, Multicenter, Open-Label, Randomized Controlled StudyZhenbin Wei, Rongrong Liu, Lingling Shi, et al.
The Lancet. Haematology|February 7, 2025
Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trialSijian Yu, Fen Huang, Na Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2023
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III TrialYiwen Ling, Li Xuan, Na Xu, et al.
Pageof 4